APO Research
Talk to an analyst

APO RESEARCH · REPORT

Mantle Cell Lymphoma Therapeutics

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Mantle Cell Lymphoma Therapeutics Market Outlook and Growth Opportunities 2026

22 December 2025197 pages

Choose your research edition.

Industry ResearchMantle Cell Lymphoma Therapeutics Industry Research Report 2026118 pages · $2,950 USDIndustry Growth & TrendsGlobal Mantle Cell Lymphoma Therapeutics Industry Growth and Trends Forecast to 203289 pages · $3,450 USDMarket StructureGlobal Mantle Cell Lymphoma Therapeutics Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032187 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Mantle Cell Lymphoma Therapeutics Market Outlook and Growth Opportunities 2026197 pages · $4,250 USDMarket Analysis & ForecastGlobal Mantle Cell Lymphoma Therapeutics Market Analysis and Forecast 2026-2032193 pages · $4,950 USD

Market perspective

The global Mantle Cell Lymphoma Therapeutics market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Mantle Cell Lymphoma Therapeutics is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Mantle Cell Lymphoma Therapeutics is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Mantle Cell Lymphoma Therapeutics is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Mantle Cell Lymphoma Therapeutics market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Mantle Cell Lymphoma Therapeutics market include Takeda Pharmaceutical Co. Ltd., Johnson & Johnson Services Inc., AstraZeneca Plc, Celgene Corp. and Allergan Plc, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global Mantle Cell Lymphoma Therapeutics market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Mantle Cell Lymphoma Therapeutics and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Mantle Cell Lymphoma Therapeutics revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Mantle Cell Lymphoma Therapeutics market.

Mantle Cell Lymphoma Therapeutics Segment by Company

Takeda Pharmaceutical Co. Ltd.

Johnson & Johnson Services Inc.

AstraZeneca Plc

Celgene Corp.

Allergan Plc

Mantle Cell Lymphoma Therapeutics Segment by Type

Combination Therapy

Monotherapy

Mantle Cell Lymphoma Therapeutics Segment by Application

Hospital

Research Institute

Other

Mantle Cell Lymphoma Therapeutics Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Colombia

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Mantle Cell Lymphoma Therapeutics status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Mantle Cell Lymphoma Therapeutics key companies, revenue, market share, and recent developments.

3. To split the Mantle Cell Lymphoma Therapeutics breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Mantle Cell Lymphoma Therapeutics market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Mantle Cell Lymphoma Therapeutics significant trends, drivers, influence factors in global and regions.

6. To analyze Mantle Cell Lymphoma Therapeutics competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Mantle Cell Lymphoma Therapeutics market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Mantle Cell Lymphoma Therapeutics and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Mantle Cell Lymphoma Therapeutics.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Mantle Cell Lymphoma Therapeutics industry.

Chapter 3: Detailed analysis of Mantle Cell Lymphoma Therapeutics company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Mantle Cell Lymphoma Therapeutics in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Mantle Cell Lymphoma Therapeutics in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Mantle Cell Lymphoma Therapeutics Industry Trends Table 2. Mantle Cell Lymphoma Therapeutics Industry Drivers Table 3. Mantle Cell Lymphoma Therapeutics Industry Opportunities and Challenges Table 4. Mantle Cell Lymphoma Therapeutics Industry Restraints Table 5. Global Mantle Cell Lymphoma Therapeutics Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Mantle Cell Lymphoma Therapeutics Revenue Share by Company (2021-2026) Table 7. Global Mantle Cell Lymphoma Therapeutics Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Mantle Cell Lymphoma Therapeutics Key Company Manufacturing Base & Headquarters Table 9. Global Mantle Cell Lymphoma Therapeutics Company, Product Type & Application Table 10. Global Mantle Cell Lymphoma Therapeutics Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Mantle Cell Lymphoma Therapeutics by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Combination Therapy Table 15. Significant Companies of Monotherapy Table 16. Global Mantle Cell Lymphoma Therapeutics Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 17. Global Mantle Cell Lymphoma Therapeutics Sales Value by Type (2021-2026) & (US$ Million) Table 18. Global Mantle Cell Lymphoma Therapeutics Sales Value by Type (2027-2032) & (US$ Million) Table 19. Global Mantle Cell Lymphoma Therapeutics Sales Value Share by Type (2021-2026) Table 20. Global Mantle Cell Lymphoma Therapeutics Sales Value Share by Type (2027-2032) Table 21. Significant Companies of Hospital Table 22. Significant Companies of Research Institute Table 23. Significant Companies of Other Table 24. Global Mantle Cell Lymphoma Therapeutics Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global Mantle Cell Lymphoma Therapeutics Sales Value by Application (2021-2026) & (US$ Million) Table 26. Global Mantle Cell Lymphoma Therapeutics Sales Value by Application (2027-2032) & (US$ Million) Table 27. Global Mantle Cell Lymphoma Therapeutics Sales Value Share by Application (2021-2026) Table 28. Global Mantle Cell Lymphoma Therapeutics Sales Value Share by Application (2027-2032) Table 29. Global Mantle Cell Lymphoma Therapeutics Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 30. Global Mantle Cell Lymphoma Therapeutics Sales Value by Region (2021-2026) & (US$ Million) Table 31. Global Mantle Cell Lymphoma Therapeutics Sales Value Share by Region (2021-2026) Table 32. Global Mantle Cell Lymphoma Therapeutics Sales Value by Region (2027-2032) & (US$ Million) Table 33. Global Mantle Cell Lymphoma Therapeutics Sales Value Share by Region (2027-2032) Table 34. Global Mantle Cell Lymphoma Therapeutics Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 35. Global Mantle Cell Lymphoma Therapeutics Sales Value by Country (2021-2026) & (US$ Million) Table 36. Global Mantle Cell Lymphoma Therapeutics Sales Value Market Share by Country (2021-2026) Table 37. Global Mantle Cell Lymphoma Therapeutics Sales Value by Country (2027-2032) & (US$ Million) Table 38. Global Mantle Cell Lymphoma Therapeutics Sales Value Market Share by Country (2027-2032) Table 39. Takeda Pharmaceutical Co. Ltd. Company Information Table 40. Takeda Pharmaceutical Co. Ltd. Business Overview Table 41. Takeda Pharmaceutical Co. Ltd. Mantle Cell Lymphoma Therapeutics Revenue (US$ Million) and Gross Margin (2021-2026) Table 42. Takeda Pharmaceutical Co. Ltd. Mantle Cell Lymphoma Therapeutics Product Portfolio Table 43. Takeda Pharmaceutical Co. Ltd. Recent Development Table 44. Johnson & Johnson Services Inc. Company Information Table 45. Johnson & Johnson Services Inc. Business Overview Table 46. Johnson & Johnson Services Inc. Mantle Cell Lymphoma Therapeutics Revenue (US$ Million) and Gross Margin (2021-2026) Table 47. Johnson & Johnson Services Inc. Mantle Cell Lymphoma Therapeutics Product Portfolio Table 48. Johnson & Johnson Services Inc. Recent Development Table 49. AstraZeneca Plc Company Information Table 50. AstraZeneca Plc Business Overview Table 51. AstraZeneca Plc Mantle Cell Lymphoma Therapeutics Revenue (US$ Million) and Gross Margin (2021-2026) Table 52. AstraZeneca Plc Mantle Cell Lymphoma Therapeutics Product Portfolio Table 53. AstraZeneca Plc Recent Development Table 54. Celgene Corp. Company Information Table 55. Celgene Corp. Business Overview Table 56. Celgene Corp. Mantle Cell Lymphoma Therapeutics Revenue (US$ Million) and Gross Margin (2021-2026) Table 57. Celgene Corp. Mantle Cell Lymphoma Therapeutics Product Portfolio Table 58. Celgene Corp. Recent Development Table 59. Allergan Plc Company Information Table 60. Allergan Plc Business Overview Table 61. Allergan Plc Mantle Cell Lymphoma Therapeutics Revenue (US$ Million) and Gross Margin (2021-2026) Table 62. Allergan Plc Mantle Cell Lymphoma Therapeutics Product Portfolio Table 63. Allergan Plc Recent Development Table 64. Research Programs/Design for This Report Table 65. Authors List of This Report Table 66. Secondary Sources Table 67. Primary Sources List of Figures Figure 1. Mantle Cell Lymphoma Therapeutics Product Image Figure 2. Global Mantle Cell Lymphoma Therapeutics Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Mantle Cell Lymphoma Therapeutics Market Size (2021-2032) & (US$ Million) Figure 4. Global Mantle Cell Lymphoma Therapeutics Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Combination Therapy Image Figure 8. Monotherapy Image Figure 9. Global Mantle Cell Lymphoma Therapeutics Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 10. Global Mantle Cell Lymphoma Therapeutics Sales Value Share 2021 VS 2025 VS 2032 Figure 11. Global Mantle Cell Lymphoma Therapeutics Sales Value Share by Type (2021-2032) Figure 12. Hospital Image Figure 13. Research Institute Image Figure 14. Other Image Figure 15. Global Mantle Cell Lymphoma Therapeutics Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 16. Global Mantle Cell Lymphoma Therapeutics Sales Value Share 2021 VS 2025 VS 2032 Figure 17. Global Mantle Cell Lymphoma Therapeutics Sales Value Share by Application (2021-2032) Figure 18. Global Mantle Cell Lymphoma Therapeutics Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 19. Global Mantle Cell Lymphoma Therapeutics Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 20. North America Mantle Cell Lymphoma Therapeutics Sales Value (2021-2032) & (US$ Million) Figure 21. North America Mantle Cell Lymphoma Therapeutics Sales Value Share by Country (%), 2025 VS 2032 Figure 22. Europe Mantle Cell Lymphoma Therapeutics Sales Value (2021-2032) & (US$ Million) Figure 23. Europe Mantle Cell Lymphoma Therapeutics Sales Value Share by Country (%), 2025 VS 2032 Figure 24. Asia-Pacific Mantle Cell Lymphoma Therapeutics Sales Value (2021-2032) & (US$ Million) Figure 25. Asia-Pacific Mantle Cell Lymphoma Therapeutics Sales Value Share by Country (%), 2025 VS 2032 Figure 26. South America Mantle Cell Lymphoma Therapeutics Sales Value (2021-2032) & (US$ Million) Figure 27. South America Mantle Cell Lymphoma Therapeutics Sales Value Share by Country (%), 2025 VS 2032 Figure 28. Middle East & Africa Mantle Cell Lymphoma Therapeutics Sales Value (2021-2032) & (US$ Million) Figure 29. Middle East & Africa Mantle Cell Lymphoma Therapeutics Sales Value Share by Country (%), 2025 VS 2032 Figure 30. USA Mantle Cell Lymphoma Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 31. USA Mantle Cell Lymphoma Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 32. USA Mantle Cell Lymphoma Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 33. Canada Mantle Cell Lymphoma Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 34. Canada Mantle Cell Lymphoma Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 35. Canada Mantle Cell Lymphoma Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 36. Mexico Mantle Cell Lymphoma Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 37. Mexico Mantle Cell Lymphoma Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 38. Mexico Mantle Cell Lymphoma Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 39. Germany Mantle Cell Lymphoma Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 40. Germany Mantle Cell Lymphoma Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 41. Germany Mantle Cell Lymphoma Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 42. France Mantle Cell Lymphoma Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 43. France Mantle Cell Lymphoma Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 44. France Mantle Cell Lymphoma Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 45. U.K. Mantle Cell Lymphoma Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. U.K. Mantle Cell Lymphoma Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. U.K. Mantle Cell Lymphoma Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. Italy Mantle Cell Lymphoma Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. Italy Mantle Cell Lymphoma Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. Italy Mantle Cell Lymphoma Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. Spain Mantle Cell Lymphoma Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. Spain Mantle Cell Lymphoma Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. Spain Mantle Cell Lymphoma Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. Russia Mantle Cell Lymphoma Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. Russia Mantle Cell Lymphoma Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. Russia Mantle Cell Lymphoma Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. Netherlands Mantle Cell Lymphoma Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. Netherlands Mantle Cell Lymphoma Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. Netherlands Mantle Cell Lymphoma Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. Nordic Countries Mantle Cell Lymphoma Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. Nordic Countries Mantle Cell Lymphoma Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. Nordic Countries Mantle Cell Lymphoma Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. China Mantle Cell Lymphoma Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. China Mantle Cell Lymphoma Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. China Mantle Cell Lymphoma Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. Japan Mantle Cell Lymphoma Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. Japan Mantle Cell Lymphoma Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. Japan Mantle Cell Lymphoma Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. South Korea Mantle Cell Lymphoma Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. South Korea Mantle Cell Lymphoma Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. South Korea Mantle Cell Lymphoma Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. India Mantle Cell Lymphoma Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. India Mantle Cell Lymphoma Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. India Mantle Cell Lymphoma Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. Australia Mantle Cell Lymphoma Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. Australia Mantle Cell Lymphoma Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. Australia Mantle Cell Lymphoma Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. Southeast Asia Mantle Cell Lymphoma Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. Southeast Asia Mantle Cell Lymphoma Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. Southeast Asia Mantle Cell Lymphoma Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. Brazil Mantle Cell Lymphoma Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. Brazil Mantle Cell Lymphoma Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. Brazil Mantle Cell Lymphoma Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. Argentina Mantle Cell Lymphoma Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. Argentina Mantle Cell Lymphoma Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. Argentina Mantle Cell Lymphoma Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. Chile Mantle Cell Lymphoma Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. Chile Mantle Cell Lymphoma Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. Chile Mantle Cell Lymphoma Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Colombia Mantle Cell Lymphoma Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Colombia Mantle Cell Lymphoma Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Colombia Mantle Cell Lymphoma Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Peru Mantle Cell Lymphoma Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Peru Mantle Cell Lymphoma Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Peru Mantle Cell Lymphoma Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Saudi Arabia Mantle Cell Lymphoma Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Saudi Arabia Mantle Cell Lymphoma Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Saudi Arabia Mantle Cell Lymphoma Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Israel Mantle Cell Lymphoma Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Israel Mantle Cell Lymphoma Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Israel Mantle Cell Lymphoma Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. UAE Mantle Cell Lymphoma Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. UAE Mantle Cell Lymphoma Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. UAE Mantle Cell Lymphoma Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. Turkey Mantle Cell Lymphoma Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. Turkey Mantle Cell Lymphoma Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. Turkey Mantle Cell Lymphoma Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Iran Mantle Cell Lymphoma Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Iran Mantle Cell Lymphoma Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Iran Mantle Cell Lymphoma Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. Egypt Mantle Cell Lymphoma Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. Egypt Mantle Cell Lymphoma Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. Egypt Mantle Cell Lymphoma Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. Years Considered Figure 115. Research Process Figure 116. Key Executives Interviewed

Scope & coverage.

Types
  • Combination Therapy
  • Monotherapy
Applications
  • Hospital
  • Research Institute
  • Other
Companies covered
  • Takeda Pharmaceutical Co. Ltd.
  • Johnson & Johnson Services Inc.
  • AstraZeneca Plc
  • Celgene Corp.
  • Allergan Plc

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Mantle Cell Lymphoma Therapeutics Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Mantle Cell Lymphoma Therapeutics Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Mantle Cell Lymphoma Therapeutics Market Dynamics
  1. 2.1 Mantle Cell Lymphoma Therapeutics Industry Trends
  2. 2.2 Mantle Cell Lymphoma Therapeutics Industry Drivers
  3. 2.3 Mantle Cell Lymphoma Therapeutics Industry Opportunities and Challenges
  4. 2.4 Mantle Cell Lymphoma Therapeutics Industry Restraints
3 Mantle Cell Lymphoma Therapeutics Market by Company
  1. 3.1 Global Mantle Cell Lymphoma Therapeutics Company Revenue Ranking in 2025
  2. 3.2 Global Mantle Cell Lymphoma Therapeutics Revenue by Company (2021-2026)
  3. 3.3 Global Mantle Cell Lymphoma Therapeutics Company Ranking (2024-2026)
  4. 3.4 Global Mantle Cell Lymphoma Therapeutics Company Manufacturing Base and Headquarters
  5. 3.5 Global Mantle Cell Lymphoma Therapeutics Company Product Type and Application
  6. 3.6 Global Mantle Cell Lymphoma Therapeutics Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Mantle Cell Lymphoma Therapeutics Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Mantle Cell Lymphoma Therapeutics Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Mantle Cell Lymphoma Therapeutics Market by Type
  1. 4.1 Mantle Cell Lymphoma Therapeutics Type Introduction
  2. 4.1.1 Combination Therapy
  3. 4.1.2 Monotherapy
  4. 4.2 Global Mantle Cell Lymphoma Therapeutics Sales Value by Type
  5. 4.2.1 Global Mantle Cell Lymphoma Therapeutics Sales Value by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Mantle Cell Lymphoma Therapeutics Sales Value by Type (2021-2032)
  7. 4.2.3 Global Mantle Cell Lymphoma Therapeutics Sales Value Share by Type (2021-2032)
5 Mantle Cell Lymphoma Therapeutics Market by Application
  1. 5.1 Mantle Cell Lymphoma Therapeutics Application Introduction
  2. 5.1.1 Hospital
  3. 5.1.2 Research Institute
  4. 5.1.3 Other
  5. 5.2 Global Mantle Cell Lymphoma Therapeutics Sales Value by Application
  6. 5.2.1 Global Mantle Cell Lymphoma Therapeutics Sales Value by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Mantle Cell Lymphoma Therapeutics Sales Value by Application (2021-2032)
  8. 5.2.3 Global Mantle Cell Lymphoma Therapeutics Sales Value Share by Application (2021-2032)
6 Mantle Cell Lymphoma Therapeutics Regional Value Analysis
  1. 6.1 Global Mantle Cell Lymphoma Therapeutics Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Mantle Cell Lymphoma Therapeutics Sales Value by Region (2021-2032)
  3. 6.2.1 Global Mantle Cell Lymphoma Therapeutics Sales Value by Region: 2021-2026
  4. 6.2.2 Global Mantle Cell Lymphoma Therapeutics Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Mantle Cell Lymphoma Therapeutics Sales Value (2021-2032)
  7. 6.3.2 North America Mantle Cell Lymphoma Therapeutics Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Mantle Cell Lymphoma Therapeutics Sales Value (2021-2032)
  10. 6.4.2 Europe Mantle Cell Lymphoma Therapeutics Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Mantle Cell Lymphoma Therapeutics Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Mantle Cell Lymphoma Therapeutics Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Mantle Cell Lymphoma Therapeutics Sales Value (2021-2032)
  16. 6.6.2 South America Mantle Cell Lymphoma Therapeutics Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Mantle Cell Lymphoma Therapeutics Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Mantle Cell Lymphoma Therapeutics Sales Value Share by Country, 2025 VS 2032
7 Mantle Cell Lymphoma Therapeutics Country-level Value Analysis
  1. 7.1 Global Mantle Cell Lymphoma Therapeutics Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Mantle Cell Lymphoma Therapeutics Sales Value by Country (2021-2032)
  3. 7.2.1 Global Mantle Cell Lymphoma Therapeutics Sales Value by Country (2021-2026)
  4. 7.2.2 Global Mantle Cell Lymphoma Therapeutics Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Mantle Cell Lymphoma Therapeutics Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Mantle Cell Lymphoma Therapeutics Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Mantle Cell Lymphoma Therapeutics Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Mantle Cell Lymphoma Therapeutics Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Mantle Cell Lymphoma Therapeutics Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Mantle Cell Lymphoma Therapeutics Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Mantle Cell Lymphoma Therapeutics Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Mantle Cell Lymphoma Therapeutics Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Mantle Cell Lymphoma Therapeutics Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Mantle Cell Lymphoma Therapeutics Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Mantle Cell Lymphoma Therapeutics Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Mantle Cell Lymphoma Therapeutics Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Mantle Cell Lymphoma Therapeutics Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Mantle Cell Lymphoma Therapeutics Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Mantle Cell Lymphoma Therapeutics Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Mantle Cell Lymphoma Therapeutics Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Mantle Cell Lymphoma Therapeutics Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Mantle Cell Lymphoma Therapeutics Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Mantle Cell Lymphoma Therapeutics Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Mantle Cell Lymphoma Therapeutics Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Mantle Cell Lymphoma Therapeutics Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Mantle Cell Lymphoma Therapeutics Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Mantle Cell Lymphoma Therapeutics Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Mantle Cell Lymphoma Therapeutics Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Mantle Cell Lymphoma Therapeutics Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Mantle Cell Lymphoma Therapeutics Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Mantle Cell Lymphoma Therapeutics Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Mantle Cell Lymphoma Therapeutics Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Mantle Cell Lymphoma Therapeutics Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Mantle Cell Lymphoma Therapeutics Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Mantle Cell Lymphoma Therapeutics Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Mantle Cell Lymphoma Therapeutics Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Mantle Cell Lymphoma Therapeutics Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Mantle Cell Lymphoma Therapeutics Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Mantle Cell Lymphoma Therapeutics Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Mantle Cell Lymphoma Therapeutics Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Mantle Cell Lymphoma Therapeutics Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Mantle Cell Lymphoma Therapeutics Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Mantle Cell Lymphoma Therapeutics Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Mantle Cell Lymphoma Therapeutics Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Mantle Cell Lymphoma Therapeutics Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Mantle Cell Lymphoma Therapeutics Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Mantle Cell Lymphoma Therapeutics Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Mantle Cell Lymphoma Therapeutics Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Mantle Cell Lymphoma Therapeutics Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Mantle Cell Lymphoma Therapeutics Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Mantle Cell Lymphoma Therapeutics Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Mantle Cell Lymphoma Therapeutics Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Mantle Cell Lymphoma Therapeutics Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Mantle Cell Lymphoma Therapeutics Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Mantle Cell Lymphoma Therapeutics Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Mantle Cell Lymphoma Therapeutics Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Mantle Cell Lymphoma Therapeutics Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Mantle Cell Lymphoma Therapeutics Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Mantle Cell Lymphoma Therapeutics Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Mantle Cell Lymphoma Therapeutics Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Mantle Cell Lymphoma Therapeutics Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Mantle Cell Lymphoma Therapeutics Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Mantle Cell Lymphoma Therapeutics Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Mantle Cell Lymphoma Therapeutics Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Mantle Cell Lymphoma Therapeutics Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Mantle Cell Lymphoma Therapeutics Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Mantle Cell Lymphoma Therapeutics Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Mantle Cell Lymphoma Therapeutics Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Mantle Cell Lymphoma Therapeutics Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Mantle Cell Lymphoma Therapeutics Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Mantle Cell Lymphoma Therapeutics Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Mantle Cell Lymphoma Therapeutics Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Mantle Cell Lymphoma Therapeutics Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Mantle Cell Lymphoma Therapeutics Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Mantle Cell Lymphoma Therapeutics Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Mantle Cell Lymphoma Therapeutics Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Mantle Cell Lymphoma Therapeutics Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Mantle Cell Lymphoma Therapeutics Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Mantle Cell Lymphoma Therapeutics Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Mantle Cell Lymphoma Therapeutics Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Mantle Cell Lymphoma Therapeutics Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Mantle Cell Lymphoma Therapeutics Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Mantle Cell Lymphoma Therapeutics Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Mantle Cell Lymphoma Therapeutics Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Mantle Cell Lymphoma Therapeutics Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Mantle Cell Lymphoma Therapeutics Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Mantle Cell Lymphoma Therapeutics Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Mantle Cell Lymphoma Therapeutics Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Takeda Pharmaceutical Co. Ltd.
  2. 8.1.1 Takeda Pharmaceutical Co. Ltd. Company Information
  3. 8.1.2 Takeda Pharmaceutical Co. Ltd. Business Overview
  4. 8.1.3 Takeda Pharmaceutical Co. Ltd. Mantle Cell Lymphoma Therapeutics Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Takeda Pharmaceutical Co. Ltd. Mantle Cell Lymphoma Therapeutics Product Portfolio
  6. 8.1.5 Takeda Pharmaceutical Co. Ltd. Recent Developments
  7. 8.2 Johnson & Johnson Services Inc.
  8. 8.2.1 Johnson & Johnson Services Inc. Company Information
  9. 8.2.2 Johnson & Johnson Services Inc. Business Overview
  10. 8.2.3 Johnson & Johnson Services Inc. Mantle Cell Lymphoma Therapeutics Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Johnson & Johnson Services Inc. Mantle Cell Lymphoma Therapeutics Product Portfolio
  12. 8.2.5 Johnson & Johnson Services Inc. Recent Developments
  13. 8.3 AstraZeneca Plc
  14. 8.3.1 AstraZeneca Plc Company Information
  15. 8.3.2 AstraZeneca Plc Business Overview
  16. 8.3.3 AstraZeneca Plc Mantle Cell Lymphoma Therapeutics Revenue and Gross Margin (2021-2026)
  17. 8.3.4 AstraZeneca Plc Mantle Cell Lymphoma Therapeutics Product Portfolio
  18. 8.3.5 AstraZeneca Plc Recent Developments
  19. 8.4 Celgene Corp.
  20. 8.4.1 Celgene Corp. Company Information
  21. 8.4.2 Celgene Corp. Business Overview
  22. 8.4.3 Celgene Corp. Mantle Cell Lymphoma Therapeutics Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Celgene Corp. Mantle Cell Lymphoma Therapeutics Product Portfolio
  24. 8.4.5 Celgene Corp. Recent Developments
  25. 8.5 Allergan Plc
  26. 8.5.1 Allergan Plc Company Information
  27. 8.5.2 Allergan Plc Business Overview
  28. 8.5.3 Allergan Plc Mantle Cell Lymphoma Therapeutics Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Allergan Plc Mantle Cell Lymphoma Therapeutics Product Portfolio
  30. 8.5.5 Allergan Plc Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst